Market
Will Novo Nordisk's amycretin advance to phase 3 trials by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from Novo Nordisk or clinical trial registries
Story
Novo Nordisk Shares Surge on Amycretin Showing 22% Weight Loss Over 36 Weeks
Jan 24, 2025, 12:09 PM
Novo Nordisk A/S shares surged after the company announced promising early-stage trial results for its new obesity treatment, amycretin. The phase 1b/2a trial, involving 125 participants with overweight or obesity, demonstrated that amycretin, administered as a once-weekly subcutaneous injection, led to an average weight loss of 9.7% after 20 weeks, 16.2% after 28 weeks, and 22% after 36 weeks. In comparison, participants receiving a placebo experienced an average weight gain of about 2%. The drug, a unimolecular GLP-1 and amylin receptor agonist, showed a safety profile consistent with incretin-based therapies, with the most common side effects being gastrointestinal and generally mild to moderate in severity. 'We are very encouraged by the subcutaneous phase 1b/2a results for amycretin in people living with overweight or obesity,' said Martin Lange, executive vice president for Development at Novo Nordisk. Based on these results, Novo Nordisk plans to further develop amycretin for adults with overweight or obesity.
View original story
Similar markets
Yes • 50%
No • 50%
Negative results • 25%
Positive results • 25%
Trial halted • 25%
Mixed results • 25%
No • 50%
Yes • 50%
Pursue mergers or acquisitions • 25%
Increase investment in marketing existing drugs • 25%
Develop a new obesity drug • 25%
Focus on improving CagriSema • 25%
Yes • 50%
No • 50%
Haemophilia treatment • 25%
No approval • 25%
Multiple treatments • 25%
Other rare disease treatment • 25%